IRIS Accounts Production v25.2.0.378 06596885 Board of Directors 1.6.24 31.5.25 31.5.25 19/9/2025 false true false false true false Auditors Opinion iso4217:GBP iso4217:USD iso4217:EUR xbrli:shares xbrli:pure utr:tonnes utr:kWh 06596885 2024-05-31 06596885 2025-05-31 06596885 2024-06-01 2025-05-31 06596885 2023-05-31 06596885 2023-06-01 2024-05-31 06596885 2024-05-31 06596885 ns15:EnglandWales 2024-06-01 2025-05-31 06596885 ns14:PoundSterling 2024-06-01 2025-05-31 06596885 ns10:Director1 2024-06-01 2025-05-31 06596885 ns10:PrivateLimitedCompanyLtd 2024-06-01 2025-05-31 06596885 ns10:SmallEntities 2024-06-01 2025-05-31 06596885 ns10:Audited 2024-06-01 2025-05-31 06596885 ns10:SmallCompaniesRegimeForDirectorsReport 2024-06-01 2025-05-31 06596885 ns10:SmallCompaniesRegimeForAccounts 2024-06-01 2025-05-31 06596885 ns10:FullAccounts 2024-06-01 2025-05-31 06596885 ns10:Director2 2024-06-01 2025-05-31 06596885 ns10:Director3 2024-06-01 2025-05-31 06596885 ns10:Director4 2024-06-01 2025-05-31 06596885 ns10:Director5 2024-06-01 2025-05-31 06596885 ns10:CompanySecretary1 2024-06-01 2025-05-31 06596885 ns10:RegisteredOffice 2024-06-01 2025-05-31 06596885 ns5:CurrentFinancialInstruments 2025-05-31 06596885 ns5:CurrentFinancialInstruments 2024-05-31 06596885 ns5:ShareCapital 2025-05-31 06596885 ns5:ShareCapital 2024-05-31 06596885 ns5:SharePremium 2025-05-31 06596885 ns5:SharePremium 2024-05-31 06596885 ns5:FurtherSpecificReserve1ComponentTotalEquity 2025-05-31 06596885 ns5:FurtherSpecificReserve1ComponentTotalEquity 2024-05-31 06596885 ns5:RetainedEarningsAccumulatedLosses 2025-05-31 06596885 ns5:RetainedEarningsAccumulatedLosses 2024-05-31 06596885 ns5:PlantMachinery 2024-06-01 2025-05-31 06596885 ns5:FurnitureFittings 2024-06-01 2025-05-31 06596885 ns5:ComputerEquipment 2024-06-01 2025-05-31 06596885 ns5:PlantMachinery 2024-05-31 06596885 ns5:FurnitureFittings 2024-05-31 06596885 ns5:ComputerEquipment 2024-05-31 06596885 ns5:PlantMachinery 2025-05-31 06596885 ns5:FurnitureFittings 2025-05-31 06596885 ns5:ComputerEquipment 2025-05-31 06596885 ns5:PlantMachinery 2024-05-31 06596885 ns5:FurnitureFittings 2024-05-31 06596885 ns5:ComputerEquipment 2024-05-31 06596885 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2025-05-31 06596885 ns5:WithinOneYear ns5:CurrentFinancialInstruments 2024-05-31

REGISTERED NUMBER: 06596885 (England and Wales)

| FINANCIAL STATEMENTS |

| FOR THE YEAR ENDED 31 MAY 2025 |

| FOR |

| APEX MOLECULAR LIMITED |

| APEX MOLECULAR LIMITED (REGISTERED NUMBER: 06596885) |

CONTENTS OF THE FINANCIAL STATEMENTS

for the Year Ended 31 May 2025

Page |

| Company Information | 1 |

| Statement of Financial Position | 2 |

| Notes to the Financial Statements | 3 |

| APEX MOLECULAR LIMITED |

COMPANY INFORMATION

for the Year Ended 31 May 2025

| DIRECTORS: | Dr P Jackson

| Dr T E O Screen

| Dr S A Brown

| Dr A Flinn

| M Warburton

| SECRETARY: | S D Hoskins

| REGISTERED OFFICE: | Block 19 Alderley Park

| Mereside

| Alderley Edge

| Cheshire

| SK10 4TG

| REGISTERED NUMBER: | 06596885 (England and Wales)

| AUDITORS: | Fairhurst Audit Services Ltd

| Statutory Auditor

| Chartered Accountants

| Douglas Bank House

| Wigan Lane

| Wigan

| Lancashire

| WN1 2TB

| APEX MOLECULAR LIMITED (REGISTERED NUMBER: 06596885) |

STATEMENT OF FINANCIAL POSITION

31 May 2025

| 2025 | 2024 |

| Notes | £ | £ | £ | £ |

FIXED ASSETS

Tangible assets | 4 | 21,922 |  | 152,305 |  |

CURRENT ASSETS

Debtors | 5 | 501,490 |  | 652,674 |  |

Cash at bank and in hand | 793,014 |  | 1,236,916 |  |

1,294,504 |  | 1,889,590 |  |

CREDITORS

Amounts falling due within one year | 6 | 246,956 |  | 397,848 |  |

NET CURRENT ASSETS | 1,047,548 |  | 1,491,742 |  |

TOTAL ASSETS LESS CURRENT LIABILITIES | 1,069,470 |  | 1,644,047 |  |

CAPITAL AND RESERVES

Called up share capital | 311,719 |  | 311,719 |  |

Share premium | 647,168 |  | 647,168 |  |

Other reserves | 6,330 |  | 6,330 |  |

Retained earnings | 104,253 |  | 678,830 |  |

1,069,470 |  | 1,644,047 |  |

The financial statements have been prepared and delivered in accordance with the provisions applicable to companies subject to the small companies regime.

In accordance with Section 444 of the Companies Act 2006, the Income Statement has not been delivered.

The financial statements were approved by the Board of Directors and authorised for issue on 19 September 2025 and were signed on its behalf by:

Dr S A Brown - Director

| APEX MOLECULAR LIMITED (REGISTERED NUMBER: 06596885) |

NOTES TO THE FINANCIAL STATEMENTS

for the Year Ended 31 May 2025

1. | STATUTORY INFORMATION

| Apex Molecular Limited is a private company, limited by shares , registered in England and Wales. The company's registered number and registered office address can be found on the Company Information page.

| The presentation currency of the financial statements is the Pound Sterling (£).

2. | ACCOUNTING POLICIES

| Basis of preparing the financial statements

| These financial statements have been prepared in accordance with Financial Reporting Standard 102 "The Financial Reporting Standard applicable in the UK and Republic of Ireland" including the provisions of Section 1A "Small Entities" and the Companies Act 2006. The financial statements have been prepared under the historical cost convention.

| Going concern

| At the time of approving the financial statements, the directors have a reasonable expectation that the company has sufficient resources to continue in operational existence for the foreseeable future and the directors continue to adopt the going concern basis of accounting in preparing the financial statements.

| Turnover

| Turnover is measured at the fair value of the consideration received or receivable, excluding discounts, rebates, value added tax and other sales taxes.

| Tangible fixed assets

| Depreciation is provided at the following annual rates in order to write off the cost less estimated residual value of each asset over its estimated useful life or, if held under a finance lease, over the lease term, whichever is the shorter.

| Plant and machinery | - | 25% on reducing balance

| Fixtures and fittings | - | 33% on reducing balance

| Computer equipment | - | 25% on reducing balance

| Taxation

| Taxation for the year comprises current and deferred tax. Tax is recognised in the Income Statement, except to the extent that it relates to items recognised in other comprehensive income or directly in equity.

| Current or deferred taxation assets and liabilities are not discounted.

| Current tax is recognised at the amount of tax payable using the tax rates and laws that have been enacted or substantively enacted by the statement of financial position date.

| Deferred tax

| Deferred tax is recognised in respect of all timing differences that have originated but not reversed at the statement of financial position date.

| Timing differences arise from the inclusion of income and expenses in tax assessments in periods different from those in which they are recognised in financial statements. Deferred tax is measured using tax rates and laws that have been enacted or substantively enacted by the year end and that are expected to apply to the reversal of the timing difference.

| Unrelieved tax losses and other deferred tax assets are recognised only to the extent that it is probable that they will be recovered against the reversal of deferred tax liabilities or other future taxable profits.

| Research and development

| Expenditure on research and development is written off in the year in which it is incurred.

| APEX MOLECULAR LIMITED (REGISTERED NUMBER: 06596885) |

NOTES TO THE FINANCIAL STATEMENTS - continued

for the Year Ended 31 May 2025

2. | ACCOUNTING POLICIES - continued

| Hire purchase and leasing commitments

| Assets obtained under hire purchase contracts or finance leases are capitalised in the balance sheet. Those held under hire purchase contracts are depreciated over their estimated useful lives. Those held under finance leases are depreciated over their estimated useful lives or the lease term, whichever is the shorter.

| The interest element of these obligations is charged to profit or loss over the relevant period. The capital element of the future payments is treated as a liability.

| Pension costs and other post-retirement benefits

| Payments to defined contribution retirement benefit schemes are charged as an expense to the profit and loss as they fall due.

3. | EMPLOYEES AND DIRECTORS

| The average number of employees during the year was 33 (2024 - 38 ) .

4. | TANGIBLE FIXED ASSETS

| Fixtures |

| Plant and |  | and |  | Computer |

| machinery |  | fittings |  | equipment |  | Totals

£ | £ | £ | £ |

| COST

| At 1 June 2024 | 820,051 |  | 6,904 |  | 25,283 |  | 852,238 |  |

| Additions | 6,110 |  | - |  | 585 |  | 6,695 |  |

| At 31 May 2025 | 826,161 |  | 6,904 |  | 25,868 |  | 858,933 |  |

| DEPRECIATION

| At 1 June 2024 | 674,558 |  | 6,686 |  | 18,689 |  | 699,933 |  |

| Charge for year | 134,953 |  | 55 |  | 2,070 |  | 137,078 |  |

| At 31 May 2025 | 809,511 |  | 6,741 |  | 20,759 |  | 837,011 |  |

| NET BOOK VALUE

| At 31 May 2025 | 16,650 |  | 163 |  | 5,109 |  | 21,922 |  |

| At 31 May 2024 | 145,493 |  | 218 |  | 6,594 |  | 152,305 |  |

| The net book value of tangible fixed assets includes £NIL (2024 - £ 25,975 ) in respect of assets held under hire purchase contracts.

5. | DEBTORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Trade debtors | 339,836 |  | 465,469 |  |

| Tax | 4,706 |  | 39,954 |  |

| Prepayments | 156,948 |  | 147,251 |  |

501,490 |  | 652,674 |  |

| APEX MOLECULAR LIMITED (REGISTERED NUMBER: 06596885) |

NOTES TO THE FINANCIAL STATEMENTS - continued

for the Year Ended 31 May 2025

6. | CREDITORS: AMOUNTS FALLING DUE WITHIN ONE YEAR |

2025 | 2024 |

£ | £ |

| Bank loans and overdrafts | 10,532 |  | 5,353 |  |

| Hire purchase contracts | - |  | 34,188 |  |

| Trade creditors | 70,469 |  | 82,041 |  |

| Social security and other taxes | 50,537 |  | 51,785 |  |

| VAT | 76,696 |  | 138,751 |  |

| Accruals and deferred income | 38,722 |  | 85,730 |  |

246,956 |  | 397,848 |  |

7. | DISCLOSURE UNDER SECTION 444(5B) OF THE COMPANIES ACT 2006

| The Report of the Auditors was unqualified.

| Jane Dennis BA (Hons) FCA (Senior Statutory Auditor)

| for and on behalf of Fairhurst Audit Services Ltd

8. | ULTIMATE CONTROLLING PARTY

| In the opinion of the directors, there is no ultimate controlling party.